AJAshesh B. Jani

Ashesh B. Jani

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ashesh B. Jani has a total of 48 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Prostate Cancer Modality Time Trend Analyses From 1973 to 2004

    by Ashesh B. Md Jani, Peter A. S. Md Johnstone, Stanley L. Liauw, Viraj A. Master, Peter J. Rossi

    Objectives: Although specialized (urology/radiotherapy [RT]) databases have been used to measure practice patterns in nonmetastatic prostate cancer, the Surveillance, Epidemiology, and End Results (SEER) registry has not yet been employed for this task in detail. Our objectives were to analyze time trends in the use of surgery and RT and type of RT (external beam RT [EBRT], brachytherapy [Brachy] or combination EBRT + Brachy [Combo]). Methods: Eight lakh twenty-three thousand two hundred ninety-four patients in the SEER public-use registry (1973–2004) were identified. Modality time-trend curves were plotted for the whole group and by (a) grade (well-differentiated [WD], moderately differentiated [MD], and poorly differentiated [PD]) and (b) stage (modified AJCC stage 0-I, stage II, and stage III). A nonparametric (Spearman) test was used to assess correlation of diagnosis year with (a) percentage use of RT and (b) percentage use of EBRT, Brachy, and Combo. Results: RT use steadily increased from 9.1% in 1973 to 26.0% in 2004 (P < 0.001). Within RT, EBRT use decreased from 99.3% to 59.3% (P < 0.001), Brachy use increased from 0.0% to 29.6% (P < 0.001), and Combo use increased from 0.0% to 11.1% (P < 0.001). Similar time-trend curves to the overall group were observed for all grades and for stage 0 to II patients; stage III time trends were somewhat more static. Conclusions: Our SEER analysis demonstrated an expected rise in RT use (and relative increase in Brachy) paralleling the rise in evidence for modern EBRT and Brachy efficacy/safety. Within stated limitations, these results can serve as national benchmarks to assess prevailing referral patterns in a given institution or region.


  • Pelvic Shape and Prostate Motion

    by Ashesh B. Jani, Timothy H. Fox, Deborah Blaustein, Peter J. Rossi, Peter A. Johnstone, Viraj A. Master

    To study the impact of pelvic shape on prostate motion and the implications for radiotherapy target design and treatment outcomes. A total of 3741 measurements (daily shift moves in the 3 principal directions) on 29 consecutive prostate cancer patients were reviewed. All patients had 3 prostatic fiducials placed and were tracked using kilovoltage on-board imaging. Pelvic shape was categorized into android (n = 21; 2580 measurements) and gynecoid (n = 8; 1161 measurements) (defined geometrically by postoutlet to preoutlet ratio). Multivariate analyses of means/standard deviations in each principal direction were performed using major demographic, disease, anatomic, and treatment factors as covariates. Toxicity rates were compared using Fisher exact test. On simple t test comparisons, no mean/standard deviation reached significance, although there was a nonsignificant (0.38 vs. 0.31 cm, P = 0.083) larger mean antero-posterior (AP) movement in the gynecoid group. On multivariate analyses, gynecoid shape (P = 0.032) significantly predicted for mean AP movement, and gynecoid shape (P = 0.045) significantly predicted for standard deviation of AP movement. Pelvic AP and RL dimensions also correlated with mean and standard movement along the respective axes. There were no differences between rates of acute (GI or GU) toxicity (P = 0.456) between the android and gynecoid groups. Treatment strategies that do not employ daily motion tracking may require wider planning target volume margins in gynecoid patients. Tracking the prostate daily, as done in our case using fiducials/on-board imaging, can counter differences in pelvic shape to produce similar treatment outcomes.


  • Case Study of Anti-1-Amino-3-F-18 Fluorocyclobutane-1-Carboxylic Acid (Anti-[F-18] FACBC) to Guide Prostate Cancer Radiotherapy Target Design

    by Ashesh B. Jani, Timothy H. Fox, Daisy Whitaker, David M. Schuster

    Anti-1-amino-3-F-18 fluorocyclobutane-1-carboxylic acid (FACBC) is a novel radiotracer, which has shown some promise for use with positron emission tomography (PET)/computed tomography (CT) for visualizing prostate cancer. Here we describe a case of a prostate cancer patient who underwent radiation treatment and had an FACBC scan obtained as part of a pilot study. We explored the potential impact of FACBC on treatment planning. We registered the FACBC acquisition with the PET/CT, which required a simple translation. Then, we did a deformable image registration of the PET/CT with the planning CT-this process allowed the FACBC-defined gross tumor volume (GTVFACBC) to be projected into the planning CT. An intensity-modulated radiotherapy (IMRT) plan (plan A) not including GTVFACBC (with final dose to 81.0 Gy) was generated, as was an IMRT plan including the GTVFACBC to a final dose of 86.4 Gy (plan B). Target coverage and normal tissue dose volume histogram (DVH) endpoints were tabulated. In this particular patient, bladder constraints could not be met on any plan due to anatomic limitations. However, the impact on the rectal DVH could be assessed, and inclusion of the GTVFACBC did permit rectal DVH constraints to be met in plan B while maintaining target coverage and inhomogeneity constraints. In our test case, it was feasible to use FACBC to guide IMRT, and highlights the role of deformable image registration of the PET/CT with the planning CT. These findings can guide future studies incorporating FACBC into treatment planning.


  • Age and Grade Trends in Prostate Cancer (1974–2003)

    by Ashesh B. Jani, Peter A. S. Johnstone, Stanley L. Liauw, Viraj A. Master, Otis W. Brawley

    Age and pathologic grade are 2 critical factors used to guide clinical decisions and comparative outcomes studies in prostate cancer. The objective of this investigation was to use the Surveillance, Epidemiology, and End Results (SEER) registry to examine time trends in age and grade. The SEER public-use registry was queried by year of diagnosis from 1974 to 2003 for age at diagnosis (40–49, 50–59, 60–69, 70–79, and 80+ years) and for pathologic grade [well differentiated (WD), moderately differentiated (MD), and poorly differentiated (PD) disease]. Results were tabulated by 5-year interval; a total of 455,170 patients were included in the analysis. Time-trends analyses were performed for age, for grade, and for age and grade simultaneously, in each case applying a multivariate χ2 test. Five-year cause specific survival (CSS) rates were also tabulated by age and grade. Overall, there was a nonsignificant (P = 0.68) change in distribution of age at diagnosis. However, a significant (P < 0.001) grade migration took place over the study period, principally from WD to MD disease, and occurred across all age groups. Five-year cause specific survival time trends were similar for all age groups, but WD appeared to converge with MD disease in later years. An overall grade migration has occurred in prostate cancer, primarily observed as a shift from WD to MD disease; this may weaken grade-based prognostic categorizations. This migration occurred independent of patient age, reinforcing that the grade migration is likely due to changes in pathologic interpretation rather than to screening-related changes in disease characteristics.


  • Open Access

    The Role of Indium-111 Radioimmunoscintigraphy in Post-Radical Retropubic Prostatectomy Management of Prostate Cancer Patients

    by Ashesh B. Jani, Stanley L. Liauw, Michael J. Blend

    Indium-111 radioimmunoscintigraphy (RIS) has an increasing role in the treatment of prostate cancer and is most commonly performed at this disease site using labeled monoclonal antibody against prostate-specific membrane antigen. There are many limitations of RIS, including low spatial resolution, low diagnostic yield and limited availability. Despite these limitations, the efficacy of RIS has been demonstrated in many clinical studies, including multi-institutional investigations. The highest sensitivity and specificity of RIS appears to be in the post-radical retropubic prostatectomy (post-RRP) setting. RIS has recently been explored for its role in clinical radiotherapy decision-making, and was found to have a significant impact in selecting patients for radiotherapy and for the general radiotherapy treatment volume definition. RIS has also recently been explored for its role in radiotherapy planning and was found to impact clinical target volume design. However, manual editing of the RIS volume is still necessary when projected into the radiotherapy-planning scan, as there is often overlap in the RIS-defined uptake regions with normal structures (rectum, bladder and symphysis bone marrow). The impact of RIS on biochemical control has been explored, with studies in this area yielding conflicting results. It appears that the maximum impact of RIS is possible when areas of labeled antibody uptake regions are co-registered with the radiotherapy-planning computed tomography scan.The larger RIS-guided target volumes do not appear to be prohibitive in increasing radiotherapy-related toxicity. Future directions of the use of RIS for post-RRP prostate cancer are discussed.


  • Comparison of late gastrointestinal and genitourinary toxicity of prostate cancer patients undergoing intensity-modulated versus conventional radiotherapy using localized fields

    by A B Jani, A Su, D Correa, J Gratzle

    To compare late genitourinary (GU) and gastrointestinal (GI) toxicity of radiotherapy (RT) to localized fields for prostate cancer delivered using intensity-modulated RT (IMRT) versus conventional RT (ConvRT). The records of 461 patients were reviewed; 355 patients received IMRT and 106 received ConvRT. Late GU and GI toxicity were compared. Late GU toxicity rates were not significantly different (P=0.166); however, late GI toxicity rates were lower with IMRT (P=0.001). Regression analyses demonstrated that only IMRT use (P=0.006) predicted reduction in late GI toxicity but no factors correlated with late GU toxicity. IMRT did not influence late GU toxicity but was associated with a reduction of late GI toxicity over ConvRT.


  • Role of Androgen Ablation with Low-Dose-Rate Brachytherapy in the??Treatment of Prostate Cancer

    by Ashesh B. Jani, Asal Shoushtari, Jeffrey M. Feinstein

    Background:Androgen ablation is often used in addition to low-dose-rate brachytherapy in the treatment of prostate cancer, particularly for disease with adverse features. We report a...